The goal of the Diabetes Research Center is to foster and support both basic and clinical research in diabetes and related metabolic disorders with the ultimate purpose of translating findings into opportunities to prevent these diseases and to improve clinical care and outcomes.

Zepbound, or tirzepatide, was associated with nearly 50% more weight loss than Wegovy, or semaglutide, in a 72-week study published in The New England Journal of Medicine. Participants on Zepbound lost, on average, 50 pounds, compared with 33 pounds for those taking Wegovy. Both drugs, which mimic hormones that regulate appetite, had similar side effects, primarily mild gastrointestinal issues.

 Full Story: The Associated Press (5/11)  

The FDA has delayed publicly posting more than a dozen food safety warning letters because the employees who were tasked with reviewing such letters ahead of publication were fired, according to agency staff. The letters, which highlight significant violations, are a key enforcement tool and a public record of a company’s food safety practices. The FDA has rehired some staff, but a backlog remains.

 Full Story: NBC News (5/9)  

Research published in the Journal of Pediatric Endocrinology and Metabolism found early screening for celiac disease in children with newly diagnosed type 1 diabetes is beneficial. Out of 1,292 children screened, 142 had positive tests for celiac disease.

Full Story: Gastroenterology Advisor (5/12)  

The study published in Diabetes Care highlights that islet autoantibodies positivity is linked with faster onset of diabetes and beta-cell dysfunction in children with acute recurrent and chronic pancreatitis. Autoantibody-positive children showed higher HbA1c levels and lower C-peptide levels compared to those without autoantibodies.

Full Story: Endocrinology Advisor (5/13)  

Sodium-glucose cotransporter 2 inhibitors may significantly increase the risk of falls in individuals with type 2 diabetes, and the risk is even greater when these drugs are used in combination with glucagon-like peptide 1 receptor agonists, researchers reported in the journal Scientific Reports. The study followed 471 patients over a median of two years, finding that SGLT2 inhibitor use was an independent predictor of falls, while GLP-1 receptor agonist use alone was not significantly associated with fall risk.

Full Story: Medscape (4/25)  

Type 1 diabetes was associated with a higher risk of fractures, according to a study presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. The meta-analysis, which included data from 78,130 individuals across 19 countries, found that type 1 diabetes increased the risk of osteoporotic fractures in both men and women, mostly independent of femoral neck bone mineral density.

 Full Story: Endocrinology Advisor (4/24)  

Research published in the journal Diabetes Care found that 23.8% of patients with resistant type 2 diabetes also had hypercortisolism. “These results add to our understanding of why type 2 diabetes may be difficult to control in some individuals and suggest a potential role for screening for hypercortisolism in individuals in whom glycemic treatment targets are not met despite treatment with multiple medications,” researchers said.

 Full Story: Medscape (4/24)  

A study published in The Lancet Diabetes & Endocrinology reveals that Roux-en-Y gastric bypass and sleeve gastrectomy are more effective than adjustable gastric banding for severe obesity, achieving at least 50% excess weight loss in 68% and 41% of patients, respectively, compared with 25% for adjustable gastric banding. The trial involved 1,346 participants and Roux-en-Y gastric bypass was also found to be the most cost-effective option. 

 Full Story: Endocrinology Advisor (4/14)  

A small study published in The American Journal of Clinical Nutrition that included 15 participants reveals that continuous glucose monitoring devices may overestimate blood glucose levels in healthy adults, potentially leading to unnecessary dietary changes. The research highlights discrepancies between CGM readings and traditional finger-prick tests, particularly after consuming foods like smoothies and whole fruits. Experts emphasize the importance of understanding these limitations and suggest confirming CGM readings with additional methods.

 Full Story: Medscape (4/15)  

A 13-week study published in Diabetes Technology & Therapeutics found that inhaled Technosphere Insulin combined with insulin degludec offers comparable or slightly improved glycemic control for adults with type 1 diabetes compared with traditional methods like multiple daily injections and automated insulin delivery systems. The study found improvements in daytime time-in-range and A1C levels, particularly for those switching from MDI or sensor-augmented pumps. However, AID users experienced a reduction in nighttime TIR while maintaining overall glycemic control. Forty percent of participants expressed willingness to continue using TI.

 Full Story: Medical Dialogues (4/14)